Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer

Figure 1

Anti-tumor activity of gefitinib in ovarian cancer cells. (A) Human ovarian cancer cell lines were treated with the indicated concentrations of gefitinib. Cell viability was determined 72 h later. The IC50 was determined by the Chou-Talalay method. (B) Western blots showing the dose-dependent effect of gefitinib on downstream signaling in human ovarian cancer cells. SKOV3 and MDAH2774 cells were incubated with increasing amounts of gefitinib for 24 h. (C) Western blots showing the time-dependent effect of gefitinib on downstream signaling in SKOV3 cells. SKOV3 cells were incubated with 1 μM gefitinib and collected at the indicated time points. GAPDH and actin were used as a loading control for SKOV3 and MDAH2774 cells, respectively. Results are representative of 2–5 preparations.

Back to article page